CClinicalTrials.gg
Status unknownNCT03295214Updated Apr 10, 2019

Acetaminophen Given Per Os and Intravenous in Sinus Surgery

A Phase 3 interventional study of Acetaminophen in Acetaminophen, sponsored by Massachusetts Eye and Ear Infirmary. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-10.

Sponsored by Massachusetts Eye and Ear Infirmary · Phase 3, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to investigate the Visual Analog Score (VAS) for pain within the post-operative setting and determine if there is a statistically significant difference between the VAS for PO or IV acetaminophen. It is expected that in doing so the investigators can produce the maximal amount of pain relief after surgery while making conscientious monetary decisions.

Read the detailed description

Functional Endoscopic Sinus Surgery (FESS) is one of the most common Ear Nose and Throat Surgeries done in the United States annually. This procedure can vary from intense to moderate pain and as such it is difficult to properly gauge and treat postoperative pain in these patients. Commonly used in these cases, opioid drugs are given to provide adequate analgesia, however higher opioid usage is observed to cause increased Post-Anesthesia Care Unit (PACU) stays, respiratory complications and Postoperative Nausea and Vomiting (PONV). Acetaminophen is commonly used as an adjunct in these circumstances because of its opioid sparing properties.

Acetaminophen is a synthetic nonopioid p-aminophenol derivative available over the counter. Its properties include analgesic and antipyretic qualities and it is listed on the world health organization's list of essential medicines. The potential risks include liver damage, skin reactions and drug interactions when used with blood thinners at high doses. Acetaminophen has been extensively researched, in vitro and in vivo studies have found the drug to be safe when used at proper doses. Recently intravenous use of acetaminophen has gained popularity due to ease of use and ability to be given intraoperatively. This form of acetaminophen, although convenient, is around sixty two times the cost of oral acetaminophen. Due to this increased cost it is imperative that the investigators compare the two routes of administration in order to determine if the additional cost is justified.

02

Conditions studied

  • Acetaminophen

Keywords

  • Acetaminophen
  • Functional Endoscopic Sinus Surgery
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Willingness to participate
  • Undergoing FESS surgery at Massachusetts Eye and Ear (MEE)
  • Over the age of 18 during time of surgery
  • Weighing over 50kg

Exclusion criteria

Exclusion Criteria:

  • Severe hepatic impairment or active liver disease
  • Known hypersensitivity to acetaminophen or to any excipients in the intravenous formulation
  • chronic opioid use
  • chronic pain
  • alcohol or drug abuse
04

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Active comparator
    Acetaminophen 975mg Per Os

    975mg of Acetaminophen given by mouth

    Drug: Acetaminophen

  • Active comparator
    Acetaminophen 1000mg Intravenous

    1000mg of Acetaminophen given intravenously

    Drug: Acetaminophen

Interventions

  • DrugAcetaminophen

    Acetaminophen given for pain relief

05

What researchers measure

Primary outcomes

  1. VAS for pain

    First VAS pain score applied

    Time frame: 0-1 hour

Secondary outcomes

  1. Opioid Use

    Postoperative opioid consumption for pain control

    Time frame: 24 hours

  2. Time in PACU

    Time required to be admitted and discharged home

    Time frame: 3-5 hours

  3. VAS for pain

    Second VAS pain score applied

    Time frame: 1-2 hours

  4. VAS for pain

    Third VAS pain score applied

    Time frame: 2-3 hours

  5. VAS for pain

    Last VAS pain score applied

    Time frame: 24 hours

  6. PONV

    Incidence of PONV

    Time frame: 24 hours

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Carroll NV, Miederhoff PA, Cox FM, Hirsch JD. Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting. J Clin Anesth. 1994 Sep-Oct;6(5):364-9. doi: 10.1016/s0952-8180(05)80004-2. PubMed 7986507 ↗
  • DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998 Jan;86(1):102-6. doi: 10.1097/00000539-199801000-00020. PubMed 9428860 ↗
  • Fenlon S, Collyer J, Giles J, Bidd H, Lees M, Nicholson J, Dulai R, Hankins M, Edelman N. Oral vs intravenous paracetamol for lower third molar extractions under general anaesthesia: is oral administration inferior? Br J Anaesth. 2013 Mar;110(3):432-7. doi: 10.1093/bja/aes387. Epub 2012 Dec 6. PubMed 23220855 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03295214
Lead sponsor
Massachusetts Eye and Ear Infirmary
Responsible party
Luliu Fat (Principal Investigator, Massachusetts Eye and Ear Infirmary) — Principal investigator
First posted
Sep 27, 2017
Start date
Mar 28, 2018
Primary completion
Mar 2020 (estimated)
Completion
Mar 2020 (estimated)
Last update
Apr 10, 2019

Study contacts

Amy Quinkert, PhD
Contact
amy_quinkert@meei.harvard.edu
6175734192
Iuliu Fat, MD
Contact
iuliu_fat@meei.harvard.edu
617-573-3380
Iuliu Fat, MD
principal investigator · MEEI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion